Ischemia Reperfusion Injury - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB504240871

Publication Date:

April 3, 2024

Pages:

122

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.
The global market for Ischemia Reperfusion Injury was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Global Ischemia Reperfusion Injury key players include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, etc.
North America is the largest market, with a share about 50%, followed by Europe, and Japan, both have a share over 20 percent.
In terms of product, Phase 2 is the largest segment, with a share about 40%. And in terms of application, the largest application is Kidney Injury, followed by Heart Injury, Intestine Injury, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ischemia Reperfusion Injury, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Ischemia Reperfusion Injury by region & country, by Type, and by Application.
The Ischemia Reperfusion Injury market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemia Reperfusion Injury.
Market Segmentation
By Company
Angion Biomedica
Catalyst Biosciences
Ischemix Inc
Opsona Therapeutics
Pharming
TheraSource
Bolder Biotechnology
Corline Biomedical
Mifcortx
Balmes Transplantation
NovelMed Therapeutics
Hope Pharmaceuticals
Omeros Corp
Prothix
SBI Pharmaceuticals
Segment by Type:
Phase 1
Phase 2
Preclinical
Segment by Application
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Ischemia Reperfusion Injury manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Ischemia Reperfusion Injury in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Ischemia Reperfusion Injury in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Ischemia Reperfusion Injury Product Introduction
1.2 Global Ischemia Reperfusion Injury Market Size Forecast
1.3 Ischemia Reperfusion Injury Market Trends & Drivers
1.3.1 Ischemia Reperfusion Injury Industry Trends
1.3.2 Ischemia Reperfusion Injury Market Drivers & Opportunity
1.3.3 Ischemia Reperfusion Injury Market Challenges
1.3.4 Ischemia Reperfusion Injury Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Ischemia Reperfusion Injury Players Revenue Ranking (2023)
2.2 Global Ischemia Reperfusion Injury Revenue by Company (2019-2024)
2.3 Key Companies Ischemia Reperfusion Injury Manufacturing Base Distribution and Headquarters
2.4 Key Companies Ischemia Reperfusion Injury Product Offered
2.5 Key Companies Time to Begin Mass Production of Ischemia Reperfusion Injury
2.6 Ischemia Reperfusion Injury Market Competitive Analysis
2.6.1 Ischemia Reperfusion Injury Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Ischemia Reperfusion Injury Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ischemia Reperfusion Injury as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Phase 1
3.1.2 Phase 2
3.1.3 Preclinical
3.2 Global Ischemia Reperfusion Injury Sales Value by Type
3.2.1 Global Ischemia Reperfusion Injury Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Ischemia Reperfusion Injury Sales Value, by Type (2019-2030)
3.2.3 Global Ischemia Reperfusion Injury Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Heart Injury
4.1.2 Kidney Injury
4.1.3 Intestine Injury
4.1.4 Other Injury
4.2 Global Ischemia Reperfusion Injury Sales Value by Application
4.2.1 Global Ischemia Reperfusion Injury Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Ischemia Reperfusion Injury Sales Value, by Application (2019-2030)
4.2.3 Global Ischemia Reperfusion Injury Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Ischemia Reperfusion Injury Sales Value by Region
5.1.1 Global Ischemia Reperfusion Injury Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Ischemia Reperfusion Injury Sales Value by Region (2019-2024)
5.1.3 Global Ischemia Reperfusion Injury Sales Value by Region (2025-2030)
5.1.4 Global Ischemia Reperfusion Injury Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Ischemia Reperfusion Injury Sales Value, 2019-2030
5.2.2 North America Ischemia Reperfusion Injury Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Ischemia Reperfusion Injury Sales Value, 2019-2030
5.3.2 Europe Ischemia Reperfusion Injury Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Ischemia Reperfusion Injury Sales Value, 2019-2030
5.4.2 Asia Pacific Ischemia Reperfusion Injury Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Ischemia Reperfusion Injury Sales Value, 2019-2030
5.5.2 South America Ischemia Reperfusion Injury Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Ischemia Reperfusion Injury Sales Value, 2019-2030
5.6.2 Middle East & Africa Ischemia Reperfusion Injury Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Ischemia Reperfusion Injury Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Ischemia Reperfusion Injury Sales Value
6.3 United States
6.3.1 United States Ischemia Reperfusion Injury Sales Value, 2019-2030
6.3.2 United States Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Ischemia Reperfusion Injury Sales Value, 2019-2030
6.4.2 Europe Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Ischemia Reperfusion Injury Sales Value, 2019-2030
6.5.2 China Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.5.3 China Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Ischemia Reperfusion Injury Sales Value, 2019-2030
6.6.2 Japan Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Ischemia Reperfusion Injury Sales Value, 2019-2030
6.7.2 South Korea Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Ischemia Reperfusion Injury Sales Value, 2019-2030
6.8.2 Southeast Asia Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Ischemia Reperfusion Injury Sales Value, 2019-2030
6.9.2 India Ischemia Reperfusion Injury Sales Value by Type (%), 2023 VS 2030
6.9.3 India Ischemia Reperfusion Injury Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Angion Biomedica
7.1.1 Angion Biomedica Profile
7.1.2 Angion Biomedica Main Business
7.1.3 Angion Biomedica Ischemia Reperfusion Injury Products, Services and Solutions
7.1.4 Angion Biomedica Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.1.5 Angion Biomedica Recent Developments
7.2 Catalyst Biosciences
7.2.1 Catalyst Biosciences Profile
7.2.2 Catalyst Biosciences Main Business
7.2.3 Catalyst Biosciences Ischemia Reperfusion Injury Products, Services and Solutions
7.2.4 Catalyst Biosciences Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.2.5 Catalyst Biosciences Recent Developments
7.3 Ischemix Inc
7.3.1 Ischemix Inc Profile
7.3.2 Ischemix Inc Main Business
7.3.3 Ischemix Inc Ischemia Reperfusion Injury Products, Services and Solutions
7.3.4 Ischemix Inc Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.3.5 Opsona Therapeutics Recent Developments
7.4 Opsona Therapeutics
7.4.1 Opsona Therapeutics Profile
7.4.2 Opsona Therapeutics Main Business
7.4.3 Opsona Therapeutics Ischemia Reperfusion Injury Products, Services and Solutions
7.4.4 Opsona Therapeutics Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.4.5 Opsona Therapeutics Recent Developments
7.5 Pharming
7.5.1 Pharming Profile
7.5.2 Pharming Main Business
7.5.3 Pharming Ischemia Reperfusion Injury Products, Services and Solutions
7.5.4 Pharming Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.5.5 Pharming Recent Developments
7.6 TheraSource
7.6.1 TheraSource Profile
7.6.2 TheraSource Main Business
7.6.3 TheraSource Ischemia Reperfusion Injury Products, Services and Solutions
7.6.4 TheraSource Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.6.5 TheraSource Recent Developments
7.7 Bolder Biotechnology
7.7.1 Bolder Biotechnology Profile
7.7.2 Bolder Biotechnology Main Business
7.7.3 Bolder Biotechnology Ischemia Reperfusion Injury Products, Services and Solutions
7.7.4 Bolder Biotechnology Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.7.5 Bolder Biotechnology Recent Developments
7.8 Corline Biomedical
7.8.1 Corline Biomedical Profile
7.8.2 Corline Biomedical Main Business
7.8.3 Corline Biomedical Ischemia Reperfusion Injury Products, Services and Solutions
7.8.4 Corline Biomedical Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.8.5 Corline Biomedical Recent Developments
7.9 Mifcortx
7.9.1 Mifcortx Profile
7.9.2 Mifcortx Main Business
7.9.3 Mifcortx Ischemia Reperfusion Injury Products, Services and Solutions
7.9.4 Mifcortx Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.9.5 Mifcortx Recent Developments
7.10 Balmes Transplantation
7.10.1 Balmes Transplantation Profile
7.10.2 Balmes Transplantation Main Business
7.10.3 Balmes Transplantation Ischemia Reperfusion Injury Products, Services and Solutions
7.10.4 Balmes Transplantation Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.10.5 Balmes Transplantation Recent Developments
7.11 NovelMed Therapeutics
7.11.1 NovelMed Therapeutics Profile
7.11.2 NovelMed Therapeutics Main Business
7.11.3 NovelMed Therapeutics Ischemia Reperfusion Injury Products, Services and Solutions
7.11.4 NovelMed Therapeutics Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.11.5 NovelMed Therapeutics Recent Developments
7.12 Hope Pharmaceuticals
7.12.1 Hope Pharmaceuticals Profile
7.12.2 Hope Pharmaceuticals Main Business
7.12.3 Hope Pharmaceuticals Ischemia Reperfusion Injury Products, Services and Solutions
7.12.4 Hope Pharmaceuticals Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.12.5 Hope Pharmaceuticals Recent Developments
7.13 Omeros Corp
7.13.1 Omeros Corp Profile
7.13.2 Omeros Corp Main Business
7.13.3 Omeros Corp Ischemia Reperfusion Injury Products, Services and Solutions
7.13.4 Omeros Corp Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.13.5 Omeros Corp Recent Developments
7.14 Prothix
7.14.1 Prothix Profile
7.14.2 Prothix Main Business
7.14.3 Prothix Ischemia Reperfusion Injury Products, Services and Solutions
7.14.4 Prothix Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.14.5 Prothix Recent Developments
7.15 SBI Pharmaceuticals
7.15.1 SBI Pharmaceuticals Profile
7.15.2 SBI Pharmaceuticals Main Business
7.15.3 SBI Pharmaceuticals Ischemia Reperfusion Injury Products, Services and Solutions
7.15.4 SBI Pharmaceuticals Ischemia Reperfusion Injury Revenue (US$ Million) & (2019-2024)
7.15.5 SBI Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Ischemia Reperfusion Injury Industrial Chain
8.2 Ischemia Reperfusion Injury Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Ischemia Reperfusion Injury Sales Model
8.5.2 Sales Channel
8.5.3 Ischemia Reperfusion Injury Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Angion Biomedica
Catalyst Biosciences
Ischemix Inc
Opsona Therapeutics
Pharming
TheraSource
Bolder Biotechnology
Corline Biomedical
Mifcortx
Balmes Transplantation
NovelMed Therapeutics
Hope Pharmaceuticals
Omeros Corp
Prothix
SBI Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂